- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
- Lipocine to Present at 36th Annual Roth Conference
- Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
- Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
- Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
More ▼
Key statistics
On Thursday, Lipocine Inc (LPCN:NAQ) closed at 5.19, -12.77% below its 52-week high of 5.95, set on Apr 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.03 |
---|---|
High | 5.30 |
Low | 4.85 |
Bid | 5.18 |
Offer | 5.28 |
Previous close | 5.13 |
Average volume | 27.11k |
---|---|
Shares outstanding | 5.32m |
Free float | 5.15m |
P/E (TTM) | -- |
Market cap | 27.26m USD |
EPS (TTM) | -3.11 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 19:59 BST.
More ▼